Search

Your search keyword '"Loman, Laura"' showing total 129 results

Search Constraints

Start Over You searched for: Author "Loman, Laura" Remove constraint Author: "Loman, Laura"
129 results on '"Loman, Laura"'

Search Results

1. Dupilumab provides sustained effectiveness on patient-reported outcomes and favorable safety in patients with moderate-to-severe atopic dermatitis: Up to 5-year results from the daily practice BioDay registry

3. Long-Term Effectiveness and Reasons for Discontinuation of Dupilumab in Patients With Atopic Dermatitis.

4. The association between wet work and hand eczema in the Dutch general population: Application of a job exposure matrix to the lifelines cohort study.

5. A genome‐wide association study of hand eczema identifies locus 20q13.33 and reveals genetic overlap with atopic dermatitis.

6. Dupilumab provides sustained effectiveness on patient-reported outcomes and favorable safety in patients with moderate-to-severe atopic dermatitis: up to 5-year results from the daily practice BioDay Registry

7. Real-world Experience of Abrocitinib Treatment in Patients with Atopic Dermatitis and Hand Eczema: Up to 28-week Results from the BioDay Registry

9. Real-world Experience of Abrocitinib Treatment in Patients with Atopic Dermatitis and Hand Eczema: Up to 28-week Results from the BioDay Registry

10. Dupilumab in daily practice for the treatment of Pediatric Atopic Dermatitis: 16-week clinical and biomarker results from the BioDay registry

14. Chronisches Handekzem in Europa: Erfassung von Patientenerfahrungen und -perspektiven (CHEPEP) anhand von qualitativen Interviews.

15. A broad vision on hand eczema:pathogenesis, epidemiology and patient care

16. Successful tapering of dupilumab in patients with atopic dermatitis with low disease activity: a large pragmatic daily practice study from the BioDay registry

17. Validity, reliability, responsiveness and interpretability of the Recap of atopic eczema (RECAP) questionnaire

18. Which outcomes should be measured in hand eczema trials? Results from patient interviews and an expert survey

19. Successful tapering of dupilumab in patients with atopic dermatitis with low disease activity: a large pragmatic daily practice study from the BioDay registry

20. European Surveillance System on Contact Allergies (ESSCA)

22. Dupilumab in daily practice for the treatment of pediatric atopic dermatitis: 28‐week clinical and biomarker results from the BioDay registry

23. Daily Practice Experience of Baricitinib Treatment for Patients with Difficult-to-Treat Atopic Dermatitis: Results from the BioDay Registry

26. Dupilumab Drug Survival and Associated Predictors in Patients With Moderate to Severe Atopic Dermatitis

27. Lifestyle factors and hand eczema: a systematic review

29. Patient‐centered dupilumab dosing regimen leads to successful dose reduction in persistently controlled atopic dermatitis

30. Impact of the COVID-19 pandemic on adults with moderate-to-severe atopic dermatitis in the Dutch general population

31. Dupilumab Drug Survival and Associated Predictors in Patients With Moderate to Severe Atopic Dermatitis: Long-term Results From the Daily Practice BioDay Registry

32. Dupilumab in daily practice for the treatment of pediatric atopic dermatitis: 28-week clinical and biomarker results from the BioDay registry

33. Daily Practice Experience of Baricitinib Treatment for Patients with Difficult-to-Treat Atopic Dermatitis: Results from the BioDay Registry

34. Dupilumab Drug Survival and Associated Predictors in Patients With Moderate to Severe Atopic Dermatitis: Long-term Results From the Daily Practice BioDay Registry

35. Patient-centered dupilumab dosing regimen leads to successful dose reduction in persistently controlled atopic dermatitis

42. Beyond Anxiety and Depression: Loneliness and Psychiatric Disorders in Adults with Atopic Dermatitis.

45. European Surveillance System on Contact Allergies ( ESSCA ): Characteristics of patients patch tested and diagnosed with irritant contact dermatitis

48. Hyperkeratotic hand eczema: Eczema or not?

49. Hand eczema and lifestyle factors in the Dutch general population: Evidence for smoking, chronic stress, and obesity.

50. Three cases of non‐atopic hyperkeratotic hand eczema treated with dupilumab.

Catalog

Books, media, physical & digital resources